Orum Therapeutics, Inc. (KOSDAQ:475830)

South Korea · Delayed Price · Currency is KRW

62,200

+12,900 (26.17%)

Jun 29, 2026, 3:30 PM KST

229.45% (1Y)

Market Cap	1.35T +232.1%
Revenue (ttm)	20.61M -99.9%
Net Income	-48.65B
EPS	-2,263.64
Shares Out	21.72M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	313,526
Open	47,100
Previous Close	49,300
Day's Range	47,100 - 62,400
52-Week Range	17,510 - 146,600
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Orum Therapeutics

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases in South Korea and the United States. The company develops ORM-6151, which is in Phase I clinical trial for the treatment of acute myeloid leukemia and myelodysplastic syndromes; ORM-1153, which is in pre-clinical trial for the treatment of acute myeloid leukemia and hematologic malignancies; and ORM-1023, which is in pre-clinical trial for the treatment of small cell lung cancer and neuroendocrine tumo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 475830

Full Company Profile

Financial Performance

In 2025, Orum Therapeutics's revenue was 23.56 million, a decrease of -99.89% compared to the previous year's 20.91 billion. Losses were -41.97 billion, 631.2% more than in 2024.

Financial Statements